Despite Rise in Number of Erectile Dysfunction Cases, Revenue Generation from ED Drugs to Decline

Published Date : Jan 22, 2016

This is probably one of the few times when availability of certain drugs is actually hampering the growth of a certain section of the health care market. The erectile dysfunction drugs market, over the past few decades, has been driven by the rising incidence of erectile dysfunction caused by environmental and genetic factors. However, there are several forces in the coming years that are anticipated to negatively impact the erectile dysfunction drugs market, causing it to register a -4.50 per cent compound annual growth rate. The value of the global market is also projected to drop over the next three years. 

One of the most significant factors that is projected to adversely affect the prospects of erectile dysfunction drugs in the coming years is impending expiration of several blockbuster drugs. This is anticipated to make room for a host of counterfeit and generic erectile dysfunction drugs in the market. The difference in price between patented drugs and generic drugs will severely bring down the overall revenue generation of the erectile dysfunction drugs market.

Reduction in insurance coverage for the treatment of erectile dysfunction in the form of drugs has also hampered the development of the erectile dysfunction drugs market. 

There is, however, a ray of hope for the global market even amidst these negative forces. One of the most important factors that will help sustain the erectile dysfunction drugs market is the rise in geriatric population. The risk of erectile dysfunction increases with age, which means that a surge in aging population will positively drive the global market. 

Another reason for the rise in erectile dysfunction is increasing prevalence of sedentary lifestyle. A major portion of the world’s population has desk jobs and this could contribute to the risk of suffering from erectile dysfunction, thereby fueling the overall erectile dysfunction drugs market.